Nurix Therapeutics' Q3 revenue falls 37%, net loss widens

Nurix Therapeutics

09/10/2025 21:11

Overview

Nurix Q3 revenue falls to $7.9 mln, down from $12.6 mln last year

Net loss for Q3 was $86.4 mln, missing analyst expectations

Research and development expenses rose to $86.1 mln, driven by clinical trial costs

Outlook

Nurix plans pivotal trials for bexobrutideg in H2 2025

Company to provide clinical updates for bexobrutideg

Nurix advancing autoimmune drug pipeline with Gilead and Sanofi

Result Drivers

BEXOBRUTIDEG TRIALS - Nurix plans pivotal trials for bexobrutideg in relapsed/refractory CLL patients in H2 2025, aiming for accelerated approval

GS-6791 PRECLINICAL DATA - Presented data at EADV 2025 showing GS-6791's efficacy

R&D EXPENSES - Increase in R&D expenses due to accelerated enrollment and preparation for pivotal trials

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$1.03
Q3 Net Income
Miss
-$86.42 mln
-$72.30 mln (16 Analysts)
Q3 Income from Operations
Miss
-$91.38 mln
-$78.20 mln (15 Analysts)
Q3 Pretax Profit
Miss
-$86.42 mln
-$72.60 mln (14 Analysts)
Q3 Basic EPS
-$1.03
Q3 Operating Expenses
$99.27 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Nurix Therapeutics Inc is $30.50, about 67.3% above its October 8 closing price of $9.98

Press Release: ID:nGNX30779J

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)